drugset / Trial / NCT03880487
A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199
Phase 1
Terminated
26 enrolled
Kalyra Pharmaceuticals, Inc.
PRA Health Sciences · collabUnited States Department of Defense · collab
RandomizedSequentialTriple-blindTreatment
Summary
This is a Phase I, randomized, placebo and active-controlled, double blind, single and multiple ascending dose study in healthy adults to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KP-1199
Timeline
- Start
- 2019-03-12
- Primary completion
- 2020-04-21
- Completion
- 2020-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KP-1199 | Unknown | — | Oral |
| Comparator | Oxycodone | Other / unclassified | 10 mg | Oral |